Test Price
2,800 AED✅ Home Collection Available
EIF2B3 Gene Leukoencephalopathy with Vanishing White Matter Genetic Test in UAE
Executive Summary & Core Metrics
The EIF2B3 next-generation sequencing (NGS) genetic test delivers diagnostic sensitivity exceeding 99.9% for pathogenic variants causing leukoencephalopathy with vanishing white matter (VWM). Processed under ISO 9001:2015 certified workflows at DNA Labs UAE, the service integrates precision molecular analysis with comprehensive clinical support. Results are delivered within 3–4 weeks, accompanied by telephonic post-test guidance from a DHA-licensed genetics specialist.
- Accuracy Guarantee: 99.9% diagnostic sensitivity across all coding exons and flanking splice sites via NGS with bioinformatic validation.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test consultation with a Consultant Medical Genetics specialist for result interpretation and family planning.
- Insurance Verification: Direct billing confirmation via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The EIF2B3 NGS test identifies pathogenic single-nucleotide variants and small insertions or deletions across the entire coding region and conserved splice junctions of the EIF2B3 gene. This molecular analysis provides definitive genetic confirmation for individuals presenting with progressive neurological deterioration, cerebellar ataxia, or MRI evidence of diffuse white matter rarefaction consistent with vanishing white matter disease. The test supports clinical diagnosis, carrier detection, and reproductive risk assessment for families with a history of leukoencephalopathy.
| Feature | Our EIF2B3 NGS Test | Single-Gene Sanger Sequencing |
|---|---|---|
| Precision | 99.9% sensitivity across all coding exons + splice sites | ~95% sensitivity; may miss deep intronic variants |
| Methodology | Next-Generation Sequencing (NGS) with bioinformatic validation | Sanger sequencing (only targeted regions) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Report Accreditations | ISO 9001:2015, DHA-compliant, CAP-aligned | Variable; often lacks UAE statutory recognition |
Physician Insight & Safety Protocols
“Confirming a genetic diagnosis of vanishing white matter disease carries profound implications for both the patient and their extended family. The EIF2B3 NGS test provides high-confidence variant detection that must be correlated with neurological imaging and clinical presentation. At DNA Labs UAE, our post-test telephonic consultation ensures that every family receives compassionate guidance for the next steps in care and reproductive planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
Medication Advisory
Do not discontinue, adjust, or initiate any prescribed neurological medication without direct consultation with your treating physician. Genetic test results are intended to inform clinical management and should never replace professional medical advice or emergency care protocols.
Exclusion Criteria & Clinical Red Flags
Eligibility and Safety Precautions
- This test is not intended for individuals under 18 years of age without explicit parental or guardian consent in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Not available for direct-to-consumer wellness purposes; must be ordered by a licensed physician — Neurologist, Clinical Geneticist, or Pediatric Neurologist.
- If you experience sudden worsening of neurological symptoms including new-onset seizures, loss of consciousness, or severe headache, seek emergency medical care immediately.
Patient FAQ & Clinical Guidance
1. What is the EIF2B3 genetic test and who should consider it?
A: The EIF2B3 NGS test detects pathogenic variants responsible for leukoencephalopathy with vanishing white matter, a progressive neurological disorder. It is recommended for individuals with unexplained cerebellar ataxia, spasticity, or MRI evidence of symmetrical white matter rarefaction, as well as for carrier screening and reproductive planning in families with a known history of VWM.
2. How does the home collection service work for genetic testing?
A: A certified phlebotomist visits your residence between 8 AM and 11 PM using an ISO-compliant temperature-controlled cold-chain kit. The peripheral whole blood or saliva sample is transported to our DHA-licensed laboratory in Dubai Healthcare City within two hours, ensuring genomic integrity and processing readiness upon arrival.
3. How are my genetic data and privacy protected under UAE law?
A: DNA Labs UAE complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic sequence data are encrypted, stored on UAE-based servers, and never shared with third parties without prior written consent. Access is restricted to authorized clinical personnel only.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework: This genetic testing service operates under the regulatory oversight of the Dubai Health Authority (DHA) and adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) alongside Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and maintains strict data governance standards across all genomic workflows.
Clinical & Logistical Metadata
| Test Name | EIF2B3 Gene Leukoencephalopathy with Vanishing White Matter Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Saliva (Oragene DNA Collection Kit) |
| Methodology Used | Next-Generation Sequencing (NGS) targeting all coding exons and flanking splice sites of the EIF2B3 gene |
| ICD-10-CM Code | G37.8 (Other specified demyelinating diseases of central nervous system) |
| LOINC Code | 59078-9 (Genetic testing by next generation sequencing) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians